Extended collaboration with Recordati in Spain

Meda has extended its collaboration with the Italian pharma company Recordati in the cardiovascular area. A long-term agreement has been signed for Lercadip® (lercanidipine) in Spain. The product is a calcium antagonist indicated for treatment of high blood pressure. Meda takes over an existing annual turnover of about 60 MSEK from a previous licensee. Under the agreement, Meda has undertaken to pay milestones equivalent to approximately one times annual sales.

In Spain, Meda already holds marketing rights to the combination product Coripren®, lercanidipine + enalapril (a well-known ACE inhibitor). This product is intended to be launched during 2009. Marketing synergies are expected with Lercadip.

About Us

Meda is one of Europe's leading specialty pharma companies, with focus on marketing and market-adapted product development. Long-term partnerships and acquisitions are fundamental factors in its strategy.


Documents & Links